You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Can Incontinence Meds Improve Sleep Quality in Older Women?

  • Authors: News Author: Pauline Anderson; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 4/6/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 4/6/2019
Start Activity


Target Audience and Goal Statement

This article is intended for primary care physicians, obstetrician-gynecologists, neurologists, nurses, pharmacists, urologists, and other members of the healthcare team involved in the care of older women with incontinence.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe the association between antimuscarinic pharmacotherapy for urgency urinary incontinence (UUI) in older women and sleep quality, based on a planned secondary analysis from a randomized controlled trial
  2. Determine the clinical implications of the association between antimuscarinic pharmacotherapy for UUI in older women and sleep quality


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Pauline Anderson

    Freelance writer, Medscape

    Disclosures

    Disclosure: Pauline Anderson has disclosed no relevant financial relationships.

CME Author(s)

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships:
    Owns stock, stock options, or bonds from: Pfizer

Editor/CME Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    This Enduring Material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 9/1/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 0.25 AAFP Prescribed credits.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number JA0007105-0000-18-042-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Can Incontinence Meds Improve Sleep Quality in Older Women?

Authors: News Author: Pauline Anderson; CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 4/6/2018

Valid for credit through: 4/6/2019

processing....

Clinical Context

Approximately one-third to one half of women experience urinary frequency, urgency, nocturia, and/or urgency urinary incontinence (UUI). The adverse impact of UI on quality of life may include depression, limitations in daily activities, falling, fractures, and sleep disruption.

Although UUI and sleep disturbances are both common among older women and associated with one another, information to date is very limited regarding the effect of interventions specifically targeting UUI on improving sleep outcomes, and vice versa. The goal of this planned secondary analysis by Subak and colleagues from a randomized controlled trial was to examine the association between pharmacotherapy for UUI and sleep quality.

Study Synopsis and Perspective

An antimuscarinic agent used to treat UI improves sleep quality as well as bladder symptoms in older women, new research shows.

"As people age, sleep disturbances become much more common, and incontinence becomes more common, so if we have a medication that can possibly treat both, or at least by helping incontinence also help sleep, that's a tremendous benefit to patients," author Leslee L. Subak, MD, professor and chair of obstetrics and gynecology, Stanford University School of Medicine, Stanford, California, told Medscape Medical News.

The study was published online January 11 and in the February issue of Obstetrics & Gynecology.

Calms the Brain

The study was a secondary analysis of data from Bringing Simple Urge Incontinence Diagnosis and Treatment to Providers (BRIDGES), a 12-week randomized, double-blind, placebo-controlled clinical trial of fesoterodine, an antimuscarinic therapy, in ambulatory women who self-diagnosed UUI.

UUI, a condition in which the bladder muscles contract uncontrollably, can be characterized by urinary frequency, excessive nighttime urination, a sudden urge to urinate, and accidental leaks. It is 5 to 10 times more common among women than men.

Antimuscarinic medications, such as fesoterodine, help control urination by inhibiting the activity of muscarinic acetylcholine receptors. These agents "block those receptors so the bladder remains calmer," said Dr Subak.

Fesoterodine is an oral medication taken once daily. It's very commonly prescribed for overactive bladder and UUI, said Dr Subak.

In the BRIDGES multicenter trial, women were randomly assigned to placebo or to the antimuscarinic medication at a minimum dose of 4 mg and a maximum of 8 mg daily. The mean age of patients was approximately 56 years, and two-thirds of them were white.

The 2 groups were similar at baseline in terms of demographics and measures of incontinence and sleep quality.

The current analysis included 270 women in the placebo group and 277 in the treatment group.

A primary outcome was change in the Pittsburgh Sleep Quality Index (PSQI), a self-rated questionnaire that evaluates sleep quality during the past month.

The PSQI consists of 19 items weighted on a 0-to-3 scale, with a global score calculated by totaling 7 component scores. This provides an overall score ranging from 0 to 21, with lower scores indicating better sleep quality.

Another primary outcome was daytime sleepiness, as assessed with the Epworth Sleepiness Scale (ESS), which consists of 8 items measuring the likelihood of dozing or falling asleep during common daily activities, such as reading or watching television. These are rated on a scale of 0 to 3, with lower scores indicating less sleepiness.

Patients kept a diary in which they recorded each time they voided in the toilet and leaked urine and rated the severity of urgency associated with each void or incontinence episode.

Daytime Sleepiness

The study showed improvement in both groups for several sleep measures. However, women receiving antimuscarinic therapy reported significantly improved PSQI total scores compared with those receiving placebo (difference, 0.48; 95% confidence interval [CI]: 0.08, 0.89 [P =.02] after adjustment for age, race, ethnicity, clinical site, and severity of incontinence).

Compared with women receiving placebo, those in the treatment group reported significantly greater improvement on the PSQI sleep duration subscale (difference, 0.14; 95% CI: 0.03, 0.24; P =.009) and the PSQI sleep efficiency subscale (difference, 0.17; 95% CI: 0.03, 0.31; P =.02).

However, some PSQI scores (eg, the score for need for sleep medication) did not improve. The authors noted that patients may use sleep medications out of habit, and use of sleep medications may not be directly affected by improved sleep.

There was no significant difference in ESS scores between the 2 groups (P =.39). It is not clear why the medication would improve sleep quality but not reduce daytime sleepiness, said Dr Subak.

"It may be that this is a population of middle-aged and older women, and they may be used to being slightly sleep deprived and have a stable level of daytime sleepiness."

The 2 groups also had reductions in incontinence. However, women in the treatment group had a significantly greater decrease in total incontinence, UUI, and nighttime incontinence.

In addition to reducing incontinence symptoms, the medication could improve sleep because of its sedating effect. "Antimuscarinic and anticholinergic medications can produce somnolence," said Dr Subak.

In light of this new research, sleep medicine specialists should consider the impact of bladder problems on sleep dysfunction, she said.

"They should think more holistically about the effect of other organs on sleep, the bladder being one that we find to be highly correlated with sleep dysfunction," she said.

Common Sense

Commenting on the study for Medscape Medical News, Douglas Kirsch, MD, medical director, Carolinas HealthCare Sleep Medicine, clinical associate professor, Department of Medicine, UNC School of Medicine, Chapel Hill, North Carolina, and president-elect, American Academy of Sleep Medicine, said the results make sense.

"The study confirms a common sense, but unproven, theory: that better control of urinary incontinence symptoms leads to less disrupted sleep."

Dr Kirsch pointed out that patients in the study were generally not very sleepy during the day to begin with. Baseline ESS scores for the placebo and treatment groups were 6.71 and 6.47, respectively, with values of greater than 10 indicating significant sleepiness.

So he was not surprised that the scores did not change a lot at the end of the study. "There wasn't much room for improvement in terms of daytime sleepiness," he said.

"This finding demonstrates that there is not always a clear correlation between sleep disruption and daytime sleepiness."

Although generally well designed, the study did have some identified "holes," including not assessing for underlying sleep disorders, such as obstructive sleep apnea, said Dr Kirsch.

"As well, there was not an objective measurement of sleep, such as actigraphy, which could have been helpful in demonstrating improvements in sleep quality."

Pfizer Inc provided funding for the study and the study medication. Dr Subak has received research grants from Astellas Inc and was supported by a grant from the US National Institutes of Health. Dr Kirsch has disclosed no relevant financial relationships.

Obstet Gynecol. Published online January 11, 2018.[1]

Study Highlights

  • This planned secondary analysis used sleep outcomes data from a multicenter, double-blind, 12-week randomized trial of pharmacotherapy for UUI.
  • Participants (n=645; mean age, 56 ± 14 years; 68% white) were community-dwelling women self-diagnosed using the 3-Incontinence Questions questionnaire.
  • Participants were randomly assigned to receive 4 to 8 mg of antimuscarinic therapy or placebo daily.
  • Evaluation at baseline and 12 weeks included a self-reported, validated voiding diary to assess incontinence and voiding symptoms, the PSQI measuring sleep quality, and the ESS for daytime sleepiness.
  • More than half (57%) had poor sleep quality, defined as a PSQI score of more than 5.
  • Mean frequency of any UI was 4.6 episodes per day; for UUI, it was 3.9 episodes per day.
  • After 12 weeks, the antimuscarinic group vs the placebo group had greater decreases in UUI frequency (0.9 episodes per day; P <.001) and in diurnal and nocturnal voiding frequency (P <.05).
  • Sleep outcomes were also better in the antimuscarinic group than in the placebo group, with greater improvement in sleep quality (total PSQI score, 0.48; P =.02) and in sleep duration and sleep efficiency subscales (P <.05).
  • However, daytime sleepiness and use of sleep medications were comparable in both groups.
  • As a result of their findings, the investigators concluded that antimuscarinic therapy of UUI resulted in reduced frequency of incontinence and nocturia and improved overall quality, duration, and efficiency of sleep.
  • Improvements with antimuscarinic treatment in the frequency of nocturnal voids and urge incontinence reduce the number of awakenings during the night, which may result in higher sleep efficiency and longer sleep duration.
  • Fesoterodine, used as antimuscarinic therapy in this study, may have a sedating effect improving the overall quality of sleep, and this may also apply to other anticholinergic and antimuscarinic medications.
  • Because fesoterodine is an oral medication taken once daily, it is easy and convenient to use.
  • Improvement in sleep quality may be an additional benefit of UUI treatment among women, which is of clinical value because both incontinence and sleep disturbance are prevalent and bothersome conditions among middle-aged and older women.
  • In the original trial, serious adverse events were uncommon and unrelated to treatment, and no elevations of more than 250 mL occurred in posttreatment postvoid residual volume.
  • Empiric therapy for UUI therefore appears to be safe both for UUI and associated sleep disturbance.
  • Study limitations include lack of generalizability to women with more complicated histories, to men with UUI, or to women with urinary urgency but without incontinence.
  • The analysis controlled for obesity, alcohol use, and some other medical comorbidities associated with poor sleep, but not for others, such as specific sleep disorders, physical activity levels, daytime napping, or use of hypnotics.

Clinical Implications

  • A 12-week pharmacologic intervention for UUI was associated with reductions in overactive bladder symptoms and improvements in overall sleep quality, duration, and efficiency compared with a control group receiving placebo.
  • Improvement in sleep quality may be an additional benefit of UUI treatment among women, which is of clinical value because both incontinence and sleep disturbance are prevalent and bothersome conditions among middle-aged and older women.
  • Implications for the Healthcare Team: The healthcare team should bear in mind that the findings, although clinically valuable, may not apply to women with more complicated histories, to men with UUI, or to women with urinary urgency but without incontinence.

CME Test

  • Print